These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17900508)

  • 1. Potential role of the antioxidant N-acetylcysteine in slowing bone resorption in early post-menopausal women: a pilot study.
    Sanders KM; Kotowicz MA; Nicholson GC
    Transl Res; 2007 Oct; 150(4):215. PubMed ID: 17900508
    [No Abstract]   [Full Text] [Related]  

  • 2. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women.
    Henriksen DB; Alexandersen P; Hartmann B; Adrian CL; Byrjalsen I; Bone HG; Holst JJ; Christiansen C
    Bone; 2007 Mar; 40(3):723-9. PubMed ID: 17081815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of parathyroid hormone and bone resorption by calcium carbonate and calcium citrate in postmenopausal women.
    Thomas SD; Need AG; Tucker G; Slobodian P; O'Loughlin PD; Nordin BE
    Calcif Tissue Int; 2008 Aug; 83(2):81-4. PubMed ID: 18553042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in biochemical indices of bone metabolism in post-menopausal women following a dietary intervention with fortified dairy products.
    Manios Y; Moschonis G; Panagiotakos DB; Farajian P; Trovas G; Lyritis GP
    J Hum Nutr Diet; 2009 Apr; 22(2):156-65. PubMed ID: 19226352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal osteoporosis patients.
    Fernandes CE; Zerbini C; Russo LA; Albernaz MA; Eis SR; Szejnfeld VL; Pompei LM
    J Clin Densitom; 2009; 12(1):77-83. PubMed ID: 19004654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V; Stepan JJ
    Bone; 2009 Apr; 44(4):634-8. PubMed ID: 19150421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting the antioxidant potential of a common vitamin: could vitamin C prevent postmenopausal osteoporosis?
    Talaulikar VS; Chambers T; Manyonda I
    J Obstet Gynaecol Res; 2012 Jan; 38(1):253-7. PubMed ID: 21827580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of Migu tablet on bone mineral density, serum matrix metalloproteinase-2 level and bone metabolic markers in postmenopausal osteoporosis].
    Dai Y; Shen L
    Zhongguo Zhong Yao Za Zhi; 2007 Nov; 32(22):2409-12. PubMed ID: 18257271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bone turnover by milk intake in postmenopausal women.
    Bonjour JP; Brandolini-Bunlon M; Boirie Y; Morel-Laporte F; Braesco V; Bertière MC; Souberbielle JC
    Br J Nutr; 2008 Oct; 100(4):866-74. PubMed ID: 18298870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of an ipriflavone-containing supplement on urinary N-linked telopeptide levels in postmenopausal women.
    Halpner AD; Kellermann G; Ahlgrimm MJ; Arndt CL; Shaikh NA; Hargrave JJ; Tallas PG
    J Womens Health Gend Based Med; 2000 Nov; 9(9):995-8. PubMed ID: 11103099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study.
    Łukaszkiewicz J; Karczmarewicz E; Płudowski P; Jaworski M; Czerwiński E; Lewiński A; Marcinowska-Suchowierska E; Milewicz A; Spaczyński M; Lorenc RS;
    Med Sci Monit; 2008 Dec; 14(12):PH65-70. PubMed ID: 19043376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
    J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The latest from the ivd industry: prevention, diagnosis and therapy of osteoporosis.
    Clin Lab; 2005; 51(1-2):59-61. PubMed ID: 15719707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial.
    Pullerits R; d'Elia HF; Tarkowski A; Carlsten H
    Rheumatology (Oxford); 2009 Jul; 48(7):785-90. PubMed ID: 19416946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
    Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
    Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.